🏛️ Verified NIH Record • Updated 2026-08-25

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) (NCT07033494)

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Who can join: Review the eligibility criteria below.

Location: Irvine Clinical Research ( Site 1041) — Irvine, California

Age range: 50 Years to 85 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (80 Sites)

Showing the first 25 of 80 sites.

  • Irvine Clinical Research ( Site 1041) — Irvine, California
  • Healthy Brain Clinic ( Site 1005) — Long Beach, California
  • Inglewood Clinical ( Site 1062) — Los Angeles, California
  • Anderson Clinical Research ( Site 1024) — Redlands, California
  • UCSF Memory and Aging Center ( Site 1031) — San Francisco, California
  • Syrentis Clinical Research ( Site 1001) — Santa Ana, California
  • Yale University, Alzheimer's Disease Research Unit ( Site 1059) — New Haven, Connecticut
  • JEM Research Institute ( Site 1046) — Atlantis, Florida
  • Neuropsychiatric Research Center of Southwest Florida ( Site 1003) — Fort Myers, Florida
  • K2 Medical Research ( Site 1047) — Maitland, Florida
  • ClinCloud LLC ( Site 1039) — Melbourne, Florida
  • Indago Research and Health Center Inc ( Site 1044) — Miami Lakes, Florida
  • Aqualane Clinical Research ( Site 1035) — Naples, Florida
  • Suncoast Clinical Research ( Site 1007) — New Port Richey, Florida
  • Renstar Medical Research ( Site 1012) — Ocala, Florida
  • Charter Research - Orlando ( Site 1051) — Orlando, Florida
  • Axiom Brain Health ( Site 1029) — Tampa, Florida
  • K2 Medical Research ( Site 1020) — Tampa, Florida
  • Charter Research - Lady Lake ( Site 1019) — The Villages, Florida
  • Conquest Research LLC ( Site 1053) — Winter Park, Florida
  • CenExel iResearch, LLC ( Site 1015) — Decatur, Georgia
  • Alexian Brothers Medical Center-Neurosciences ( Site 1017) — Elk Grove Village, Illinois
  • Boston Center for Memory ( Site 1008) — Newton, Massachusetts
  • Clinical Research Professionals ( Site 1004) — Chesterfield, Missouri
  • The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064) — Ridgewood, New Jersey

📞 Contact the Study Coordinator

Phone: (888) 577-8839

Email: Trialsites@msd.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Early Alzheimer's Disease

Explore by condition: All Early Alzheimer's Disease clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗